Visual Investigation of Tumor‐Promoting Fibronectin Potentiated by Obesity in Pancreatic Ductal Adenocarcinoma Using an MR/NIRF Dual‐Modality Dendrimer Nanoprobe
Advanced Healthcare Materials · 2023
DOI: 10.1002/adhm.202300787 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2023. Verfasst von Tingting Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of Molecular and Functional Imaging, Department of Radiology, Zhongda Hospital, Medical School of Southeast University, Nanjin…. Hauptthemen laut MEDLINE: Fibronectins, Dendrimers, Carcinoma, Pancreatic Ductal, Obesity. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 89 Literaturangaben. Gefördert von: National Nature Science Foundation of China, Key Research and Development Program of Jiangsu Province.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease characterized by dense stroma. Obesity is an important metabolic factor that greatly increases PDAC risk and mortality, worsens progression and leads to poor chemotherapeutic outcomes. With omics analysis, magnetic resonance and near‐infrared fluorescence (MR/NIRF) dual‐modality imaging and molecular functional verification, obesity as an important risk factor is proved to modulate the extracellular matrix (ECM) components and enhance Fibronectin (FN) infiltration in the PDAC stroma, that promotes tumor progression and worsens response to chemotherapy by reducing drug delivery. In the study, to visually evaluate FN in vivo and guide PDAC therapy, an FN‐targeted nanoprobe, NP‐CREKA, is synthesized by conjugating gadolinium chelates, NIR797 and fluorescein isothiocyanate to a polyamidoamine dendrimer functionalized with targeting peptides. A dual‐modality strategy combining MR and NIRF imaging is applied, allowing effective visualization of FN in orthotopic PDAC with high spatial resolution, ideal sensitivity and excellent penetrability, especially in obese mice. In conclusion, the findings provide new insights into the potential of FN as an ideal target for therapeutic evaluation and improving treatment efficacy in PDAC, hopefully improving the specific management of PDAC in lean and obese hosts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangsu Key Laboratory of Molecular and Functional Imaging, Department of Radiology, Zhongda Hospital, Medical School of Southeast University, Nanjing, 210009, China.
ORCID-Profile: Shenghong Ju
Förderung
- National Nature Science Foundation of China
- Key Research and Development Program of Jiangsu Province
Zitieren
APA
Xu, T., Xu, X., Liu, D., Chang, D., Li, S., Sun, Y., Xie, J., & Ju, S. (2023). Visual Investigation of Tumor‐Promoting Fibronectin Potentiated by Obesity in Pancreatic Ductal Adenocarcinoma Using an MR/NIRF Dual‐Modality Dendrimer Nanoprobe. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202300787
Vancouver
Xu T, Xu X, Liu D, Chang D, Li S, Sun Y, et al. Visual Investigation of Tumor‐Promoting Fibronectin Potentiated by Obesity in Pancreatic Ductal Adenocarcinoma Using an MR/NIRF Dual‐Modality Dendrimer Nanoprobe. Advanced Healthcare Materials. 2023. doi:10.1002/adhm.202300787
BibTeX
@article{Xu2023,
author = {Xu, Tingting and Xu, Xiaoxuan and Liu, Dongfang and Chang, Di and Li, Siqi and Sun, Yeyao and Xie, Jinbing and Ju, Shenghong},
title = {Visual Investigation of Tumor‐Promoting Fibronectin Potentiated by Obesity in Pancreatic Ductal Adenocarcinoma Using an MR/NIRF Dual‐Modality Dendrimer Nanoprobe},
journal = {Advanced Healthcare Materials},
year = {2023},
doi = {10.1002/adhm.202300787}
}
EUVIMED